Christopher Sayed, MD
Dermatology · Chapel Hill, NCNPI 1225265903
Payments from drug & device makers
Across 1,047 payments — averaging $3157.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$1.1M
- AstraZeneca$1M
- AbbVie$593K
- Incyte Corporation$541K
- UCB, Inc.$27K
- Novartis$15K
- plus $22K from 8 others
Across 3 payments — averaging $641.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$1K
- UCB, Inc.$400
- Novartis$324
What the payments were for
- Consulting fees$104,45115%
- Speaking & faculty fees$511,87174%
- Travel & lodging$66,61010%
- Food & beverage$7,2111%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 42 | $1,100,053 |
| AstraZeneca | 2 | $1,008,089 |
| AbbVie | 446 | $592,674 |
| Incyte Corporation | 509 | $540,929 |
| UCB, Inc. | 15 | $27,226 |
| Novartis | 18 | $14,867 |
| UCB Biosciences Inc. | 6 | $6,500 |
| Sanofi-aventis U.S. LLC | 1 | $5,322 |
| Novartis Pharma AG | 2 | $4,725 |
| Sandoz | 1 | $3,375 |
| UCB GmbH | 2 | $1,000 |
| Almirall LLC | 1 | $800 |
| Eli Lilly | 1 | $400 |
| Regeneron Healthcare Solutions, Inc. | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,306,033 in reported general payments places this provider in the 95th percentile of 475 dermatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 86 | $1,487,300 |
| Cosentyx Unoready PenSecukinumab | 87 | $1,096,162 |
| RemicadeInfliximab | 47 | $699,614 |
| StelaraUstekinumab | 20 | $529,624 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 13 | $334,227 |
| InflectraInfliximab-Dyyb | 23 | $175,257 |
| Taltz AutoinjectorIxekizumab | 11 | $104,263 |
| ErtapenemErtapenem Sodium | 49 | $18,352 |
| Cefdinir | 37 | $2,343 |
| Doxycycline Hyclate | 49 | $1,906 |
| Tacrolimus | 11 | $1,501 |
| Clobetasol Propionate | 30 | $1,459 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 43 | $1,410 |
| Clindamycin Hcl | 37 | $1,109 |
| Metronidazole | 21 | $870 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Chapel Hill
- Aida Lugo-SomolinosChapel Hill$2.2M
- Sue Ellen CoxChapel Hill$1.8M
- Donna CultonChapel Hill$424K
- Chris AdigunChapel Hill$71K
- Priyanka VedakChapel Hill$25K
- Rosalyn GeorgeWilmington$6.5M
- Steven FeldmanWinston Salem$4.3M
- Adnan NasirRaleigh$4.1M
- Zoe DraelosHigh Point$3M
- Nicole SeminaraHuntersville$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.